DK1334194T3 - Afbildning, diagnosticering og behandling af sygdom - Google Patents

Afbildning, diagnosticering og behandling af sygdom

Info

Publication number
DK1334194T3
DK1334194T3 DK01992777T DK01992777T DK1334194T3 DK 1334194 T3 DK1334194 T3 DK 1334194T3 DK 01992777 T DK01992777 T DK 01992777T DK 01992777 T DK01992777 T DK 01992777T DK 1334194 T3 DK1334194 T3 DK 1334194T3
Authority
DK
Denmark
Prior art keywords
diagnosis
imaging
treatment
disease
materials
Prior art date
Application number
DK01992777T
Other languages
English (en)
Inventor
Lukasz Huminiecki
Roy Bicknell
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK1334194T3 publication Critical patent/DK1334194T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
DK01992777T 2000-11-06 2001-11-06 Afbildning, diagnosticering og behandling af sygdom DK1334194T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24556600P 2000-11-06 2000-11-06
US27366201P 2001-03-07 2001-03-07
PCT/GB2001/004906 WO2002036771A2 (en) 2000-11-06 2001-11-06 Imaging, diagnosis and treatment of disease

Publications (1)

Publication Number Publication Date
DK1334194T3 true DK1334194T3 (da) 2007-05-29

Family

ID=26937319

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01992777T DK1334194T3 (da) 2000-11-06 2001-11-06 Afbildning, diagnosticering og behandling af sygdom
DK06077262.1T DK1790728T3 (da) 2000-11-06 2001-11-06 Billeddannelse, diagnose og behandling af sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06077262.1T DK1790728T3 (da) 2000-11-06 2001-11-06 Billeddannelse, diagnose og behandling af sygdom

Country Status (12)

Country Link
US (5) US7498034B2 (da)
EP (2) EP1790728B1 (da)
JP (2) JP2004524821A (da)
AT (2) ATE360068T1 (da)
AU (3) AU2002223784B2 (da)
CA (1) CA2427310C (da)
CY (2) CY1107609T1 (da)
DE (2) DE60143065D1 (da)
DK (2) DK1334194T3 (da)
ES (1) ES2296829T3 (da)
PT (2) PT1790728E (da)
WO (1) WO2002036771A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223784B2 (en) * 2000-11-06 2007-01-18 Cancer ResearchTechnology Limited Imaging, diagnosis and treatment of disease
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
WO2004003163A2 (en) * 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
US7185814B2 (en) * 2002-10-16 2007-03-06 Dcard, Inc. Layer structure and method of manufacture for optical memory strip (OMS)
EP1565491B1 (en) * 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
JP2009510002A (ja) * 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
JP2010512327A (ja) * 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
AR065271A1 (es) * 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
US8399421B2 (en) * 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009046127A1 (en) * 2007-10-01 2009-04-09 Allos Therapeutics, Inc. Dt-diaphorase-active agents for treatment of pediatric tumors
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5962996B2 (ja) 2009-09-03 2016-08-03 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｌｅｃ１４ａ阻害剤
WO2011032088A1 (en) * 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
WO2011059828A1 (en) * 2009-10-29 2011-05-19 University Of Kansas Methods of producing and purifying proteins
JP5951498B2 (ja) * 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
NZ625403A (en) 2012-01-27 2016-03-31 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
TWI606065B (zh) 2012-04-27 2017-11-21 第一三共股份有限公司 抗ｒｏｂｏ４抗體
WO2014072416A1 (en) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bone metastases
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
EP3668532A4 (en) * 2017-08-19 2021-09-01 Ohio State Innovation Foundation INNOVATIVE PEPTIDE BASED CANCER IMAGING AGENTS
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co A polypeptide produced in an endothelial cell line and DNA encoding it.
WO2000053756A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999011293A1 (en) 1997-09-05 1999-03-11 Human Genome Sciences, Inc. 50 human secreted proteins
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
CA2298852A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
AU764571B2 (en) 1998-04-09 2003-08-21 Genset S.A. 5' ESTs and encoded human proteins
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001012671A1 (en) * 1999-08-12 2001-02-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr16
WO2001023523A2 (en) 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
AU2002223784B2 (en) * 2000-11-06 2007-01-18 Cancer ResearchTechnology Limited Imaging, diagnosis and treatment of disease
WO2003075860A2 (en) 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP1565491B1 (en) * 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Also Published As

Publication number Publication date
DE60127986T2 (de) 2008-01-17
ATE360068T1 (de) 2007-05-15
AU2378402A (en) 2002-05-15
EP1790728A3 (en) 2007-06-13
CA2427310A1 (en) 2002-05-10
CY1110967T1 (el) 2015-06-11
AU2007201584A1 (en) 2007-05-03
US20080145359A1 (en) 2008-06-19
PT1334194E (pt) 2007-07-17
PT1790728E (pt) 2010-11-12
ES2296829T3 (es) 2008-05-01
WO2002036771A3 (en) 2002-09-06
DE60143065D1 (de) 2010-10-21
JP2010248210A (ja) 2010-11-04
EP1334194B1 (en) 2007-04-18
DK1790728T3 (da) 2010-12-06
US7740830B2 (en) 2010-06-22
DE60127986D1 (de) 2007-05-31
ATE480622T1 (de) 2010-09-15
US7498034B2 (en) 2009-03-03
JP5603145B2 (ja) 2014-10-08
CY1107609T1 (el) 2013-03-13
EP1790728A2 (en) 2007-05-30
US20090191572A1 (en) 2009-07-30
US20080219924A1 (en) 2008-09-11
US20070025913A1 (en) 2007-02-01
EP1334194A2 (en) 2003-08-13
AU2002223784B2 (en) 2007-01-18
EP1790728B1 (en) 2010-09-08
JP2004524821A (ja) 2004-08-19
US20040071711A1 (en) 2004-04-15
WO2002036771A2 (en) 2002-05-10
US8216584B2 (en) 2012-07-10
US7582440B2 (en) 2009-09-01
US20080274045A9 (en) 2008-11-06
CA2427310C (en) 2013-12-17

Similar Documents

Publication Publication Date Title
DK1334194T3 (da) Afbildning, diagnosticering og behandling af sygdom
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1196444T3 (da) Exendin-4-konjugater og deres medicinske anvendelighed
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DK1419154T3 (da) Rapamycin-29-enoler
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
DK1163904T3 (da) Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DK0981343T3 (da) Probucolmonoestere til behandling af kardiovaskulær og inflammatorisk sygdom
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DK3449934T3 (da) Behandling af glycogenlagringssygdom type II
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
ATE506959T1 (de) Verwendung von il-18 inhibitoren
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
NO20053903D0 (no) Nukleotidlipidesterderivater.
NO20060420L (no) 2-aminobenzoylderivater
DK1328289T3 (da) Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
DK1253935T3 (da) Anvendelse af placenta-vækstfaktor til forebyggelse eller behandling af iskæmiske sygdomme eller slagtilfælde
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
DE10045123B8 (de) Das C. albicans TEC1 GEN(CaTEC1) und das kodierte Tec1p Protein
IT249540Y1 (it) Protesi totale del ginocchio.